Malaria Vaccine: AMA1-C1

$1,260,732ZIAFY2011AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 22508415 Paper 22107848 Paper 21799809 Paper 21695140 Paper 21440641 Paper 20565971 Paper 20519960 Paper 19874925 Paper 19712767 Paper 19439523 Paper 19428923 Paper 19410624 Paper 19234231 Paper 19052315 Paper 18698359 Paper 18270560 Paper 17940609 Paper 17923516 Paper 16434128

Abstract

In collaboration with Oxford University, a small Phase 2a challenge study was conducted where volunteers were immunized with AMA1-C1/Alhydrogel+CPG 7909, followed by a challenge dose of erythrocytes infected with malaria parasites. A significant correlation was observed between parasite multiplication rate and both vaccine-induced growth-inhibitory activity and AMA1 antibody titers. However, this did not translate to an overall observable clinically relevant vaccine effect in these volunteers. Currently the collaboration with Oxford University continues in a prime-boost study where volunteers are primed with viral-vectored AMA1 vaccines followed by a booster dose of AMA1-C1/Alhydrogel+CPG 7909.

View original record on NIH RePORTER →